A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Conditions: Cervical Cancer; Microsatellite Instability (MSI)-High Endometrial Cancer; Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]); Esophageal Cancer; Hepatocellular Carcinoma; Melanoma (Uveal Melanoma Excluded); Merkel Cell Carcinoma; Mesothelioma; MSI-high Colorectal Cancer; Non-small Cell Lung Cancer (NSCLC); Ovarian Cancer; Squamous Cell Carcinoma of the Head and Neck (SCCHN); Small Cell Lung Cancer (SCLC); Renal Cell Carcinoma (RCC); Triple-negative Breast Cancer; Urothelial Carcinoma; Diffuse Lar ge B-cell Lymphoma Intervention: Biological: INCAGN02385 Sponsor: Incyte Biosciences International Sàrl Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials